<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Canavan, Neil</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Flockhart, David</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Tamoxifen Metabolism, SSRIs, and the Cancer Patient</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2008</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2008-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">26-27</style></pages><abstract><style  face="normal" font="default" size="100%">For patients with comorbid medical conditions, knowledge of drug metabolism is important and may in fact be critical in the oncology setting. A case in point is the widespread use of the anti-estrogen compound tamoxifen, which acts via estrogen receptor modulation. Unfortunately, one of the more common adverse events that occur with this drug is hot flashes, a condition that is uncomfortable to the point of discouraging long-term treatment adherence. An attempt to resolve this discomfort may result in additional unforeseen risk.</style></abstract><number><style face="normal" font="default" size="100%">3</style></number><volume><style face="normal" font="default" size="100%">8</style></volume></record></records></xml>